沙美特罗氟替卡松联合噻托溴铵治疗中重度慢性阻塞性肺疾病的临床观察

Clinical observation of salmeterol and fluticasone propionate combined with tiotropium in the treatment of severe chronic obstructive pulmonary disease

目的:探讨沙美特罗氟替卡松联合塞托溴铵治疗重度慢性阻塞性肺疾病(COPD)的临床疗效。方法:收治重度COPD患者60例,分为两组。试验组给予沙美特罗氟替卡松联合塞托溴铵治疗,对照组给予沙美特罗氟替卡松治疗,比较两组临床疗效。结果:治疗后,两组FVC、FEV1、FEV1/FVC比较,差异具有统计学意义(P<0.05)。治疗后,两组SaO_2、PaCO_2、PaO_2比较,差异具有统计学意义(P<0.05)。结论:沙美特罗氟替卡松联合噻托溴铵治疗重度COPD患者临床疗效显著,可改善患者肺功能。

Objective:To investigate the clinical curative effect of salmeterol and fluticasone propionate combined with tiotropium in the treatment of severe chronic obstructive pulmonary disease(COPD).Methods:60 cases of patients with severe COPD were divided into two groups.The patients in the experimental group were treated with salmeterol and fluticasone propionate combined with tiotropium.The patients in the control group were treated with salmeterol and fluticasone propionate.The clinical curative effect of two groups was compared.Results:After treatment,the differences of the FVC,FEV1,FEV1/FVC between groups were statistically significant(P < 0.05).After treatment,the differences of the SaO2,PaCO2,PaO2 between groups were statistically significant(P < 0.05).Conclusion:Salmeterol and fluticasone propionate combined with tiotropium in the treatment of patients with severe chronic obstructive pulmonary disease had remarkable clinical curative effect and it could improve the pulmonary function of patients.